🇺🇸 FDA
Company

Sarepta

Sarepta Therapeutics

SRPT pharma USA

Quick answer

Sarepta is a pharma company (SRPT) headquartered in CAMBRIDGE, MA, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Casimersen

Duchenne Muscular Dystrophy

Phase 3 · small_molecule · terminated

1 trials project

Eteplirsen

Muscular Dystrophy, Duchenne

Phase 3 · small_molecule · active

2 trials project

SRP-4045

Duchenne Muscular Dystrophy

Phase 3 · small_molecule · completed

2 trials project

SRP-9003

Limb-girdle Muscular Dystrophy

Phase 3 · mab · active

2 trials project

SRP-9005

Muscular Dystrophies, Limb-Girdle

Phase 3 · mab · terminated

1 trials project

delandistrogene moxeparvovec

Duchenne Muscular Dystrophy

Phase 3 · gene_therapy · active

7 trials project

eteplirsen

Duchenne Muscular Dystrophy (DMD)

Phase 3 · small_molecule · completed

2 trials project

AVI-4065 Injection

Hepatitis C

Phase 2 · small_molecule · terminated

1 trials project

AVI-4658 (Eteplirsen)

Duchenne Muscular Dystrophy (DMD)

Phase 2 · small_molecule · completed

1 trials project

AVI-4658 (Eteplirsen)

Duchenne Muscular Dystrophy

Phase 2 · small_molecule · completed

1 trials project

AVI-4658 (PMO)

Duchenne Muscular Dystrophy

Phase 2 · small_molecule · completed

1 trials project

AVI-4658 for Injection

Duchenne Muscular Dystrophy

Phase 2 · small_molecule · completed

1 trials project

AVI-5126

Cardiovascular Disease

Phase 2 · small_molecule · terminated

1 trials project

Amondys 45

Duchenne Muscular Dystrophy

Phase 2 · small_molecule · completed

1 trials project

Eteplirsen

Duchenne Muscular Dystrophy

Phase 2 · small_molecule · terminated

2 trials project

Placebo

Duchenne Muscular Dystrophy

Phase 2 · small_molecule · completed

1 trials project

RESTEN-MP

Coronary Artery Disease

Phase 2 · small_molecule · completed

2 trials project

SRP-5051

Muscular Dystrophy, Duchenne

Phase 2 · small_molecule · terminated

2 trials project

SRP-9003

Limb-Girdle Muscular Dystrophy, Type 2E

Phase 2 · gene_therapy · terminated

1 trials project

SRP-9004

Limb-Girdle Muscular Dystrophy, Type 2D

Phase 2 · gene_therapy · completed

1 trials project

Vesleteplirsen

Duchenne Muscular Dystrophy

Phase 2 · small_molecule · terminated

1 trials project

delandistrogene moxeparvovec

Muscular Dystrophy, Duchenne

Phase 2 · gene_therapy · active

2 trials project

AVI-4020 Injection

West Nile Fever

Phase 1 · small_molecule · terminated

1 trials project

AVI-4020 Injection

West Nile Virus

Phase 1 · small_molecule · completed

1 trials

Drugs (3)

drug

casimersen

AMONDYS 45

 drug

eteplirsen

EXONDYS 51

 drug

golodirsen

VYONDYS 53

Patents (8)

patent

US 12377150

Exon skipping oligomer conjugates for muscular dystrophy

Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12370261

Chimeric peptides for antisense delivery

Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12286630

Treatment methods for muscular dystrophy

Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12239715

Peptide oligonucleotide conjugates

Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12168059

Trimeric peptides for antisense delivery

Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12138312

Cell-penetrating peptides for antisense delivery

Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12139709

Antisense oligomers and methods of using the same for treating diseases associat

Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12121532

Modified antisense oligomers for exon inclusion in spinal muscular atrophy

Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)